Collaboration, License, and Other Agreements - Sanofi, Antibody Narrative (Details) - Sanofi Collaboration Agreement, Antibody |
6 Months Ended |
|---|---|
Jun. 30, 2026 | |
| Disaggregation of Revenue [Line Items] | |
| Starting share of profits outside the United States, based on sales, for collaborating party | 65.00% |
| Starting share of profits outside the United States, based on sales, for Company | 35.00% |
| Ending share of profits outside the United States, based on sales, for collaborating party | 55.00% |
| Ending share of profits outside the United States, based on sales, for Company | 45.00% |
| X | ||||||||||
- Definition On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the collaborating party. No definition available.
|
| X | ||||||||||
- Definition On a sliding scale, this element represents the ending share of profits outside the United States, based on sales, for the Company. No definition available.
|
| X | ||||||||||
- Definition On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the collaborating party. No definition available.
|
| X | ||||||||||
- Definition On a sliding scale, this element represents the starting share of profits outside the United States, based on sales, for the Company. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|